We will see
1:12 am Acceleron Pharma presents encouraging response rates and progression-free survival data in patients with advanced renal cell carcinoma
I look at it from a technical perspective. Prior to earnings yesterday the stock was clearly consolidating (waiting). Now that the data has been provided regarding their Phase 2 and Phase 3 trials the future appears to be very bright considering the block buster nature of their drugs. Furthermore you can clearly see on the chart the move up on the right shoulder of the pattern. Not just me Citi has a new $58 price target.
Good Luck. Caio
need this boost
I'm out a don the sidelines until Q1 2015 can't wait for the next Saturday Night Live performance.
On to XLRN
One point that you missed that was somewhat interesting and it occurred toward the end of the call. A gentleman asked what would be the new Directors role? Well as Sherwood stated he is a Finance guy...Hmmmm.
Two things going on here. Either he's there for M&A or dressing the company up to be sold........
TRN is more diversified, has a better balance sheet, and has a stash of CASH........
I hope the BOD had an opportunity to listen to how the CEO and the CFO mumbled their way through the Q&A session. I realize analyst questions can be somewhat vague but the responses were so difficult to understand with respect to revenue recognition, milestone payments, loss of business, new business, etc., etc., it should not be that difficult. At least three analysts just said " oh forget lets move on" because they had no idea what the responses related to more so with the CFO.
That's all they had to do with the revenue was BRIDGE this on a worksheet beginning with Y/E December 2014 revenue then adjust for the takeaways such as B&L, Milestone payments, etc., then add in the forecast for NEW business related to Monovisc, and others to get to Year End Revenue 2015.
For crying out loud if you want hire me (ex Senior Finance Executive) and I will complete it. CLARITY and TRANSPARENCY is what investors want not this SMOKE and MIRROR game.
Also for the life of me why are they unable to model their revenue now that that B&L business is done, the loss of a large amount of the milestone payments is gone, the addition of Monovisc, etc, etc.
That's why it sold off heavy today they have no credibility. Furthermore Sherwood and the CFO were mumbling to each other as to who will answer the question.
It's all about the inept management of this company. If you listened to the CC it was good until the prepared statement was completed. The Q&A session was awful. A few of the analysts that asked questions appeared to be frustrated because there was no clarity in the response. This CEO needs to step aside. I am sure he is very competent with respect to the medical side of the business but this business is going nowhere until they get a more seasoned businessman at the helm.